AtriCure (NASDAQ:ATRC) Upgraded by Zacks Research to Strong-Buy Rating

Key Points

• Zacks Research upgraded AtriCure from a "hold" to a "strong-buy", while overall analyst sentiment remains a Moderate Buy (two Strong Buy, six Buy, two Hold, one Sell) with a consensus price target of $48.71.
• AtriCure beat expectations for the quarter, reporting $0.00 EPS versus a ($0.07) consensus and revenue of $141.25M (up 14.3% YoY) and set FY2026 guidance of $0.000–0.040 EPS.
• The stock opened at $27.80 with a market cap of $1.41B and a 52‑week range of $26.62–$43.18, and insiders recently sold shares (Vinayak Doraiswamy sold 5,000 shares).

AtriCure (NASDAQ:ATRC - Get Free Report) was upgraded by research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on the company. BTIG Research reaffirmed a "buy" rating and set a $54.00 price objective on shares of AtriCure in a research report on Wednesday, February 18th. UBS Group decreased their price objective on AtriCure from $60.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday, February 18th. Citigroup reaffirmed an "outperform" rating on shares of AtriCure in a research report on Wednesday, February 18th. Oppenheimer cut AtriCure from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 18th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $45.00 price objective on shares of AtriCure in a research report on Thursday, February 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $48.71.

AtriCure Trading Down 0.7%

NASDAQ:ATRC opened at $27.80 on Wednesday. The stock's 50 day moving average price is $29.24 and its 200 day moving average price is $34.28. The company has a market capitalization of $1.41 billion, a PE ratio of -278.00 and a beta of 1.28. The company has a quick ratio of 2.99, a current ratio of 3.96 and a debt-to-equity ratio of 0.13. AtriCure has a 52-week low of $26.62 and a 52-week high of $43.18.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The medical device company reported $0.00 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.07. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%.The company had revenue of $141.25 million during the quarter, compared to analysts' expectations of $139.75 million. During the same period last year, the firm earned ($0.14) EPS. The firm's revenue for the quarter was up 14.3% on a year-over-year basis. AtriCure has set its FY 2026 guidance at 0.000-0.040 EPS. On average, research analysts anticipate that AtriCure will post 0.1 EPS for the current year.

Insider Activity at AtriCure

In other news, insider Vinayak Doraiswamy sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the sale, the insider directly owned 96,875 shares of the company's stock, valued at $2,889,781.25. This trade represents a 4.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AtriCure

Several hedge funds have recently bought and sold shares of ATRC. Marshall Wace LLP increased its position in AtriCure by 63.4% during the fourth quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company's stock worth $36,136,000 after buying an additional 354,281 shares in the last quarter. Wellington Management Group LLP increased its position in AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company's stock worth $151,296,000 after buying an additional 322,818 shares in the last quarter. First Light Asset Management LLC increased its position in AtriCure by 32.0% during the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company's stock worth $46,501,000 after buying an additional 285,083 shares in the last quarter. Kennedy Capital Management LLC increased its position in AtriCure by 36.2% during the third quarter. Kennedy Capital Management LLC now owns 836,916 shares of the medical device company's stock worth $29,501,000 after buying an additional 222,529 shares in the last quarter. Finally, Norges Bank purchased a new position in AtriCure during the fourth quarter worth $8,466,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.